These findings show that it is important to understand how targeting ERK5 works — inhibition of tumour cell proliferation or survival, inhibition of tumour angiogenesis, or in appropriate models, reducing the tumour promoting role of the immune system. Here, MAPK7 is linked to neoplasm.